**Claim Version with markings showing changes made**

1. (Originally filed) A method of controlling the secretions from glands selected from the group consisting of holocrine glands, and the holocrine-like components of cerumen and mammary glands in patients whose level of glandular secretion is greater than is desirable by administering to said patient a secretorily controlling amount of botulinum toxin.

2. (Originally filed) The method of claim 1 wherein the holocrine glands are selected from the group consisting of sebaceous glands, pilosebaceous glands, meibomium glands, and glands of Zeiss and Moll.

3. (Originally filed) The method of claim 1 wherein the conditions resulting from greater then desirable levels of secretion are selected from the group consisting of seborrheic dermatitis, rhinophyma, seborrheic blepharitis, sebaceous cysts, excess cerumen, unwanted milk production, and bacterial infections of these glands resulting in hidradenitis, furuncles, carbuncles, styes and chalazions.

4. (Originally filed) The method of claim 1 wherein the method of administration is topical.

5. (Originally filed) The method of claim 1 wherein the method of administration is by injection.

6. (Originally filed) The method of claim 5 wherein injection is subdermal.

7. (Originally filed) The method of claim 5 wherein injection is transdermal.

8. (Originally filed) The method of claim 5 wherein injection is intradermal.

9. (Originally filed) The method of claim 5 wherein injection is intramuscular.

10. (Originally filed) The method of claim 6 comprising the subdermal injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

11. (Originally filed) The method of claim 10 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

12. (Originally filed) The method of claim 7 comprising the transdermal injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

13. (Originally filed) The method of claim 12 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

14. (Originally filed) The method of claim 8 comprising the intradermal injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

15. (Originally filed) The method of claim 14 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

16. (Originally filed) The method of claim 9 comprising the intramuscular injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

17. (Originally filed) The method of claim 16 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

18. (Originally filed) The method of claim 6 wherein the amount injected is between 1 and 10 U of botulinum toxin A.

19. (Originally filed) The method of claim 18 wherein the amount injected is between 2 and 3 U of botulinum toxin A.

20. (Originally filed) The method of claim 7 wherein the amount injected is between 1 and 10 U of botulinum toxin A.

21. (Originally filed) The method of claim 20 wherein the amount injected is between 2 and 3 U of botulinum toxin A.

22. (Originally filed) The method of claim 8 wherein the amount injected is between 1 and 10 U of botulinum toxin A.

23. (Originally filed) The method of claim 22 wherein the amount injected is between 2 and 3 U of botulinum toxin A.

24. (Originally filed) The method of claim 9 wherein the amount injected is between 1 and 10 U of botulinum toxin A.

25. (Originally filed) The method of claim 24 wherein the amount injected is between 2 and 3 U of botulinum toxin A.

26. (Originally filed) The method of Claim 1, wherein said method is repeated periodically to inhibit the recurrence of undesirable levels of secretion.

27. (Originally filed) The method of Claim 26, wherein said method is repeated at intervals from about 3 months to about 6 months to inhibit said recurrence.

28. (Originally filed) The method of Claim 27, wherein said method is repeated at intervals of about 4 months to inhibit said recurrence.

29. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin B.

30. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin C.

31. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin D.

32. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin E.

33. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin F.

34. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin G.

35.-44. (Cancelled)

45. (Presently amended) The method of claim [44] 56 wherein the method of administration is topical.

46. (Presently amended)The method of claim [44] 56 wherein the method of administration is by injection.

47. (Originally filed) The method of claim 46 wherein injection is subdermal.

48. (Originally filed) The method of claim 46 wherein injection is transdermal.

49. (Originally filed) The method of claim 46 wherein injection is intradermal.

50.-55. (cancelled)

56. (Presently added) . A method of smoothing fine wrinkles in the skin and decreasing the skin pore size of a subject in need of same which comprises administering to said patient a pharmacologically effective amount of botulinum toxin.